SEC Company Response from RedHill Biopharma Ltd. (RDHL) (CIK 0001553846) (RDHL) — Aug 6, 2019
RedHill Biopharma Ltd. (RDHL) (CIK 0001553846)
Date: Aug. 6, 2019 · CIK: 0001553846 · Accession: 0001171843-19-005181
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232777
Letter
RedHill Biopharma Ltd.
21 Ha'arba'a St.
Tel Aviv, 6473921, Israel
August 6, 2019
By EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
RE: RedHill Biopharma Ltd.
Registration Statement on Form F-3
Filed July 24, 2019
File No. 333-232777
Ladies and Gentlemen:
Pursuant to Rules 460 and 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, RedHill Biopharma Ltd. (the “Company”) hereby requests acceleration of the effective date of the above-mentioned Registration Statement on Form F-3 to 4:00 p.m., Eastern Time on August 8, 2019, or as soon thereafter as practicable.
Should any member of the staff of the U.S. Securities and Exchange Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
Very truly yours,
RedHill Biopharma Ltd.
Show Raw Text
CORRESP
1
filename1.htm
RedHill Biopharma Ltd.
21 Ha'arba'a St.
Tel Aviv, 6473921, Israel
August 6, 2019
By EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
RE:
RedHill Biopharma Ltd.
Registration Statement on Form F-3
Filed July 24, 2019
File No. 333-232777
Ladies and Gentlemen:
Pursuant to Rules 460 and 461 of the Rules
and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933,
as amended, RedHill Biopharma Ltd. (the “Company”) hereby requests acceleration of the effective date of the
above-mentioned Registration Statement on Form F-3 to 4:00 p.m., Eastern Time on August 8, 2019, or as soon thereafter as practicable.
Should any member of the staff of the U.S. Securities
and Exchange Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone,
LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
Very truly yours,
RedHill Biopharma Ltd.
By:
/s/ Dror Ben- Asher
Dror Ben-Asher
Chief Executive Officer